Intelligence · Clinical pipeline
Every cannabinoid clinical trial, every investigational product and every company developing one, pulled from 13 trial registries and regulator records, tagged record by record, and kept current.
Already have access? Open the tracker →
Trial starts by year
Largest live Phase III trials, by enrolment
13 registries merged into one record per trial. Website snapshot of 24 Aug 2026.
The problem
Ask how many cannabinoid trials are running and you will get a different answer from every source, because every source counts a different thing. ClinicalTrials.gov holds 1,546 of the records here and misses 750 more that only exist in the Australian, German, Indian, Dutch, Brazilian, Iranian or EU registers.
Where the 2,296 records come from
What the data shows
The analysis below is drawn straight from the tracked base. Every chart carries the figure it was built from and the basis it was counted on.
Trial starts by year, split by phase
Swipe the chart sideways →
Phase IPhase IIPhase IIIPhase IVObservational and other
Cannabinoid research did not peak and fade. Starts climbed from 54 in 2016 to a record 176 in 2025 and have held above 150 a year since 2021. But look at the gold band: Phase III has never exceeded 26 starts in a year. The field is getting bigger, not further along.
Basis: registered start year. 537 of 2,296 records carry no start date and are excluded; 2026 counts every start registered for the year, including dates still ahead. Cannamonitor Clinical Trials database, 13 registry sources, n = 2,296. Snapshot 24 Aug 2026.
Three things the record says
Where the pipeline sits
Phase II 625Other 613Phase I 382Observational 310Phase III 276Phase IV 88
Phase II is the structural engine at 625 trials. Pivotal work, Phase III and IV together, is 364, or 16% of everything on record.
Two preclinical records are too few to draw. ‘Other’ covers trials carrying no conventional phase label.
What it is being tested on
The largest single block is not a therapy. Substance-use research (616) plus healthy-volunteer and mechanistic work (274) accounts for 39% of all tags: research about cannabis, not medicine made from it.
Condition groups are multi-tag, so tags exceed the trial count. Nine of 15 groups shown.
Who pays for it
All trialsPhase III / IV
Academia runs the pipeline and industry runs the end of it. Universities fund 1,537 trials but only 183 late-phase ones. Industry funds 433, and 36% of all late-phase work.
Funder type is multi-tag. A trial with no recorded funder is excluded from both bars.
The two biggest sponsors, side by side
Trials sponsoredof them Phase III / IV
Yale has sponsored 71 cannabinoid trials and not one of them is late-phase. Jazz has sponsored 65 and 43 of them are. That contrast is the structural problem in one row.
Sponsor as recorded on the registry entry.
What is being put in the capsule
Whole-plantIsolateSynthetic
Synthetic cannabinoids have fallen from 20% of starts to 6% while isolates nearly doubled to 35%. Whole-plant preparations held roughly half the field throughout.
Share of trials with a registered start date in each era, by compound class (99.9% field coverage). The THC:CBD ratio field covers only 48% of the base and is not used.
The molecules actually under study
CBD is the most-studied cannabinoid (1,217 trials), ahead of THC (815). Behind them the minor-cannabinoid tail is real but still small: 90 trials across CBN, CBG, THCV, CBDV, delta-8-THC, CBDA and CBC combined.
Multi-tag: a trial testing a THC:CBD product carries both. 588 trials record no specific cannabinoid.
How rigorous it actually is
Placebo-controlledRandomised
The charge that cannabinoid evidence is anecdotal does not survive the phase data. 74% of Phase III trials are placebo-controlled, against 68% at Phase II and 42% at Phase I. The closer to approval, the tighter the control.
Share of each phase’s trials.
How big the trials actually are
The average cannabinoid Phase III enrols 174 patients. A mainstream pivotal trial runs several times that. Across all 1,371 Phase I to IV trials on record, total enrolment is 111,886 people.
Mean recorded sample size per phase, from the 1,252 phased trials that record one. Observational studies are excluded.
Volume and maturity live in different places
The country that runs the most trials runs the least pivotal work. 8% of US trials are Phase III, against 43% in the UK and 17% in Germany. Europe carries 185 Phase III site-tags to North America’s 92.
Phase III as a share of each country’s trial tags; the bar axis stops at 50%. 1,957 of 2,296 records carry a country.
What comes back out
30%of completed trials have posted results
Results posted 216No results posted 333Not recorded 170
Of 719 completed trials, only 216 have posted results, which is 30%. Seven in ten finished studies have never returned a public read, and only 269 records across the whole base carry a publication or DOI.
Completed trials only. ‘Not recorded’ means the registry entry carries no results field.
The products
A trial is an event and a product is a bet. The investigational-products tracker holds every cannabinoid asset in human development: what it is made of, how it is delivered, what it is aimed at, and how far it has got.
What they are made of
All productsApproved or Phase III
What they are aimed at
CBD isolates lead on count, at 38 products. But look at the gold bars: the plant-derived classes convert to a late-stage asset at close to one in five, while only 2 of the 20 synthetic small molecules have got there, and one of those two is discontinued.
Composition class and lead condition group as recorded on the product. 5 products carry no class; 6 carry no recorded stage. Eight of 11 condition groups shown.
5 Phase III programmes are recorded as discontinued. A pipeline view that quietly drops its failures tells a rosier story than the field has had.
The shelf
This is the entire licensed cannabinoid shelf, worldwide. Three are dronabinol, which is synthetic THC, and one is nabilone, a synthetic analogue of it. That leaves three distinct medicines: a balanced botanical spray, a CBD isolate and, since June 2026, the first high-THC full-spectrum botanical.
CINV; AIDS-related anorexia
Synthetic THCChemotherapy-induced nausea
Synthetic THC analogueMS spasticity
THC:CBD combinationCINV; AIDS-related anorexia
Synthetic THCRefractory epilepsies
CBD isolateChronic low-back pain
Full-spectrum botanicalCINV; AIDS-related anorexia
Synthetic THCFirst approval in any market, from the investigational-products tracker. Generic dronabinol carries no single authorisation date and is shown without one (n/d) rather than guessed.
The companies
The company tracker holds every business we can identify running, or having run, a clinical trial of a proprietary cannabinoid product in humans, with its lead asset, its lead indication, its furthest stage and the route it chose.
How far each company has got
59 of 83 companies have never got a product past Phase II. 13 sit at Phase III and 6 hold an approval.
Furthest stage reached across all of a company’s assets.
Which route they chose
Single-molecule / synthetic 49Full-spectrum botanical 25Mixed 8
Nearly six in ten chose a single molecule or a synthetic, the route with clean composition-of-matter IP. Only 25 went after the whole-plant botanical, the route that has just produced the field’s newest approval.
Strategic approach across the 82 companies with a route recorded.
Where they are based
The US leads with 29 companies, but Australia is second with 14, ahead of Canada, Israel and the UK, and far ahead of Germany at 4 despite Germany hosting the newest approval.
Headquarters country. Six of 13 shown.
The six with a marketing authorisation
The pipeline tracker
One form opens the tracker itself: the products, the companies behind them and the full analysis of the trial base you have been reading extracts from.
Already have access? Open the tracker →
Free with a work email.
If the form does not load, write to info@cannamonitor.com and we will send you access.
How we build it
How complete the record is, of 2,296 trials
Two fields are absent from every chart on this page. The THC:CBD ratio is recorded on only 48% of records, so the compound-class chart uses a field with 99.9% coverage instead. Recruitment status was defaulted by the import for 1,025 records from registries that do not maintain one, so this page counts what is recruiting (427) and what is completed (719), and says which.
Sources: ClinicalTrials.gov, EU CTR (EudraCT), CTIS, ANZCTR, ISRCTN, DRKS, NTR, CTRI, REBEC, IRCT, UMIN, ChiCTR and company disclosures. Cannamonitor Clinical Trials database, 13 registry sources, n = 2,296. Snapshot 24 Aug 2026. This page is a snapshot; the tracker is updated between snapshots.
The data behind this page
Everything above is one subject, drawn from eight data layers. In Decide those same layers cover 125+ markets and they cross-link, so a trial reaches its product, its sponsor, that company’s deals and earnings, and the market it will launch into. Choose a layer to see inside it.
| Trial | Indication | n | Status |
|---|---|---|---|
| VER-01 radicular | Radicular low-back pain | 810 | Registered |
| PROMOTE | Clinical high-risk psychosis | 586 | Registered |
| ZYN002 open-label ext. | Fragile X syndrome | 550 | Recruiting |
| CBD TPM capsules | Primary insomnia | 519 | Recruiting |
| Product | Company | Lead indication | Class |
|---|---|---|---|
| Exilby follow-on (VER-01 radicular) | Vertanical | Radicular low-back pain | Full‑spectrum |
| CANPAIN | Celadon | Chronic non-cancer pain | Full‑spectrum |
| NTI164 | Neurotech International | Paediatric neurodevelopment | Full‑spectrum |
| YCJ-01 | Oils4Cure | TSC epilepsy (adjunct) | Full‑spectrum |
| Linked record | Value |
|---|---|
| Marketing authorisation | Germany, Jun 2026 |
| Registered trials | 3 (Phase III) |
| Lead indication | Chronic low-back pain |
| Company financials | 🔒 |
| Company | Line | Latest |
|---|---|---|
| Jazz Pharmaceuticals | Epidiolex net revenue, 2025 | $1.1bn (+9%) |
| Jazz Pharmaceuticals | Epidiolex share of group revenue | ~25% |
| CNX Therapeutics | Sativex revenue, 2025 | $16.3m |
| Vertanical | Exilby revenue, company projection | >$2bn in 2 years |
| Date | Parties | Value | Type |
|---|---|---|---|
| May 2021 | Jazz Pharmaceuticals → GW Pharmaceuticals | $7.2bn | Acquisition, closed |
| Nov 2018 | Constellation Brands → Canopy Growth (38%) | C$5.0bn | Equity raise, closed |
| Oct 2025 | Jazz → CNX Therapeutics (Sativex) | Undisclosed | Divestment |
| Aug 2026 | Curaleaf → Aurora Cannabis | US$4.00/share | Announced, proposed |
| Market | Trials | Phase III | Share |
|---|---|---|---|
| United States | 908 | 74 | 8% |
| United Kingdom | 113 | 49 | 43% |
| Germany | 136 | 23 | 17% |
| Australia | 66 | 15 | 23% |
Go deeper
Go deep · Decide
The tracker gives you the analysis. Decide gives you the record, which you can query, filter and join across markets and companies.
Stay current · Essentials
Essentials keeps you current on every market: the full monthly brief the moment it is written, the news dashboard, and premium insights on the readouts and approvals that move a programme.
2,296 on our record as of 24 Aug 2026, merged from 13 registry sources. That is higher than most published counts because most published counts are a ClinicalTrials.gov search, which holds 1,546 of these and misses 750 that exist only in ANZCTR, DRKS, CTRI, ISRCTN, REBEC, IRCT, NTR, UMIN, ChiCTR or the EU registers.
Because the field behind that number is not reliable yet. A recent back-population added 1,025 records from registries that do not maintain a live recruitment status, and the import assigned them one. Rather than publish a number built on a default, this page counts what is recruiting (427) and what is completed (719). The status field is being cleaned, and when it is, the figure goes back on the page.
No. A multinational study registered in both ClinicalTrials.gov and a national register can appear as two records, so in August 2026 we ran a cross-registry deduplication over the whole base: 27 duplicate studies, 54 records collapsed to 27. Every merged record is still in the database with its own registry identifier, pointing at the record that survived, so nothing is lost and a future crawl cannot re-create it.
The duplication was almost entirely a European registry problem: 18% of CTIS records and 9% of Dutch NTR records were duplicates, against 0.2% of ClinicalTrials.gov. A further 35 records that look like duplicates are deliberately kept apart: a parent trial and its sub-studies, or a randomised trial and its open-label extension.
No. Nothing here is derived from a paper. Every figure is a query against a tagged database of individual trial, product and company records, and the query behind each one is recorded next to it, so refreshing this page is a re-run.
Your work email opens the pipeline tracker, free: the investigational-products database (114 assets), the pharmaceutical-companies database (83 developers) and the full clinical-trial analysis. The full clinical-trials database, the full company database and the science and studies library sit inside Decide.
Records are added and revised as registries publish. This page is stamped with the snapshot it was built from (24 Aug 2026), and the tracker is always ahead of the page.
Any trial of a cannabinoid or cannabis-derived intervention in humans: THC, CBD, the minor cannabinoids (90 trials across CBN, CBG, THCV, CBDV, delta-8-THC, CBDA and CBC), whole-plant and broad-spectrum extracts, synthetic analogues such as dronabinol and nabilone, nabiximols, and endocannabinoid-system modulators (79 trials). Observational and mechanistic studies are included and labelled.
The tracker shows you the pipeline. Decide gives you the databases underneath it, with 125+ markets beside them.
Already have access? Open the tracker →